Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lyell Immunopharma, Inc

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
From Lyell Immunopharma, Inc
Via GlobeNewswire
Tickers LYEL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.